Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

Affiliations

• ¹ The National and Kapodistrian University of Athens, Athens, Greece.
• ² Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
• ³ Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
• ⁴ Hospital de Cancer de Barretos, São Paulo, Brazil.
• ⁵ Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic.
• ⁶ Department of Haematology, General Hospital of Athens, Athens, Greece.
• ⁷ Hematology Department, University Hospital La Fe, Valencia, Spain.
• ⁸ Instituto COI de Ensino e Pesquisa and Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
• ⁹ Department of Oncology, Saint John Regional Hospital, Dalhousie University and University of New Brunswick, Saint John, New Brunswick, Canada.
• ¹⁰ Departamento de Hematología, Hospital 12 de Octubre, Complutense University, Madrid, Spain.
• ¹¹ UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
• ¹² Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, USA.
• ¹³ Department of Haematology, University College Hospital, London, UK.
• ¹⁴ Sanofi, Vitry-sur-Seine, France.
• ¹⁵ Sanofi, Chilly-Mazarin, France.
• ¹⁶ Sanofi, Cambridge, Massachusetts, USA.
• ¹⁷ Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
• ¹⁸ Department of Hemato-Oncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.